Post-marketing surveillance of free radical scavenger, oral edaravone, for the treatment of Amyotrophic Lateral Sclerosis

Post-marketing surveillance of free radical scavenger, oral edaravone, for the treatment of Amyotrophic Lateral Sclerosis - Post-marketing surveillance of free radical scavenger, oral edaravone, for the treatment of Amyotrophic Lateral Sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050955

Enrollment

350

Registered

2023-05-15

Start date

2023-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ALS patients who receive an edaravone product for the first time

Exclusion criteria

Exclusion criteria: ALS patients who meet contraindications to the use of edaravone

Design outcomes

Primary

Measure	Time frame
<Analysis items> 1. Types and incidences of adverse drug reactions 2. Incidence of adverse drug reactions by patient characteristics 3. Incidence of serious adverse events	—

Countries

Japan

Contacts

Public ContactKaoru Ishizaki

Tanabe Pharma Corporation Pharmacovigilance Department

tp-pms-shinchoku.JP@ml.tanabe-pharma.com03-6743-7733

Outcome results